Advertisement

Ads Placeholder
Loading...

Nicox S.A.

COX.PAEURONEXT
Healthcare
Biotechnology
0.58
0.00(0.00%)
U.S. Market opens in 55h 43m

Nicox S.A. Fundamental Analysis

Nicox S.A. (COX.PA) shows weak financial fundamentals with a PE ratio of -0.78, profit margin of -5.30%, and ROE of -43.38%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position127.39%
PEG Ratio-0.01
Current Ratio4.10

Areas of Concern

ROE-43.38%
Operating Margin-4.14%
We analyze COX.PA's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -519.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-519.4/100

We analyze COX.PA's fundamental strength across five key dimensions:

Efficiency Score

Weak

COX.PA struggles to generate sufficient returns from assets.

ROA > 10%
-29.80%

Valuation Score

Excellent

COX.PA trades at attractive valuation levels.

PE < 25
-0.78
PEG Ratio < 2
-0.01

Growth Score

Weak

COX.PA faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

COX.PA maintains a strong and stable balance sheet.

Debt/Equity < 1
0.41
Current Ratio > 1
4.10

Profitability Score

Weak

COX.PA struggles to sustain strong margins.

ROE > 15%
-4337.85%
Net Margin ≥ 15%
-5.30%
Positive Free Cash Flow
No

Key Financial Metrics

Is COX.PA Expensive or Cheap?

P/E Ratio

COX.PA trades at -0.78 times earnings. This suggests potential undervaluation.

-0.78

PEG Ratio

When adjusting for growth, COX.PA's PEG of -0.01 indicates potential undervaluation.

-0.01

Price to Book

The market values Nicox S.A. at 0.41 times its book value. This may indicate undervaluation.

0.41

EV/EBITDA

Enterprise value stands at -7.11 times EBITDA. This is generally considered low.

-7.11

How Well Does COX.PA Make Money?

Net Profit Margin

For every $100 in sales, Nicox S.A. keeps $-5.30 as profit after all expenses.

-5.30%

Operating Margin

Core operations generate -4.14 in profit for every $100 in revenue, before interest and taxes.

-4.14%

ROE

Management delivers $-43.38 in profit for every $100 of shareholder equity.

-43.38%

ROA

Nicox S.A. generates $-29.80 in profit for every $100 in assets, demonstrating efficient asset deployment.

-29.80%

Following the Money - Real Cash Generation

Operating Cash Flow

Nicox S.A. generates limited operating cash flow of $-30.94M, signaling weaker underlying cash strength.

$-30.94M

Free Cash Flow

Nicox S.A. generates weak or negative free cash flow of $-31.00M, restricting financial flexibility.

$-31.00M

FCF Per Share

Each share generates $-0.62 in free cash annually.

$-0.62

FCF Yield

COX.PA converts -79.77% of its market value into free cash.

-79.77%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.78

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.01

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.41

vs 25 benchmark

P/S Ratio

Price to sales ratio

5.54

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.41

vs 25 benchmark

Current Ratio

Current assets to current liabilities

4.10

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.43

vs 25 benchmark

ROA

Return on assets percentage

-0.30

vs 25 benchmark

ROCE

Return on capital employed

-0.26

vs 25 benchmark

How COX.PA Stacks Against Its Sector Peers

MetricCOX.PA ValueSector AveragePerformance
P/E Ratio-0.7828.45 Better (Cheaper)
ROE-43.38%763.00% Weak
Net Margin-529.55%-45265.00% (disorted) Weak
Debt/Equity0.410.34 Neutral
Current Ratio4.102795.60 Strong Liquidity
ROA-29.80%-16588.00% (disorted) Weak

COX.PA outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Nicox S.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ